These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

537 related articles for article (PubMed ID: 15676166)

  • 21. Safety and efficacy of enoxaparin compared with unfractionated heparin and oral anticoagulants for prevention of thromboembolic complications in cardioversion of nonvalvular atrial fibrillation: the Anticoagulation in Cardioversion using Enoxaparin (ACE) trial.
    Stellbrink C; Nixdorff U; Hofmann T; Lehmacher W; Daniel WG; Hanrath P; Geller C; Mügge A; Sehnert W; Schmidt-Lucke C; Schmidt-Lucke JA;
    Circulation; 2004 Mar; 109(8):997-1003. PubMed ID: 14967716
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Transesophageal echocardiographic guidance of cardioversion in patients with atrial fibrillation.
    Stoddard MF; Dawkins PR; Prince CR; Longaker RA
    Am Heart J; 1995 Jun; 129(6):1204-15. PubMed ID: 7754955
    [TBL] [Abstract][Full Text] [Related]  

  • 23. [Anticoagulation in cardioversion of atrial fibrillation. Current status and outlook for the future].
    Schimpf T; Stellbrink C
    Med Klin (Munich); 2003 Feb; 98(2):91-5. PubMed ID: 12601533
    [TBL] [Abstract][Full Text] [Related]  

  • 24. [Low molecular weight heparin and non valvular atrial fibrillation].
    Ederhy S; Di Angelantonio E; Meuleman C; Janower S; Boccara F; Cohen A
    Arch Mal Coeur Vaiss; 2006 Dec; 99(12):1210-4. PubMed ID: 18942523
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Early cardioversion of atrial fibrillation and atrial flutter guided by transoesophageal echocardiography: a single centre 8.5-year experience.
    Corrado G; Santarone M; Beretta S; Tadeo G; Tagliagambe LM; Foglia-Manzillo G; Spata M; Miglierina E; Acquati F; Santarone M
    Europace; 2000 Apr; 2(2):119-26. PubMed ID: 11225938
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Cardioversion from atrial fibrillation without prolonged anticoagulation with use of transesophageal echocardiography to exclude the presence of atrial thrombi.
    Manning WJ; Silverman DI; Gordon SP; Krumholz HM; Douglas PS
    N Engl J Med; 1993 Mar; 328(11):750-5. PubMed ID: 8437595
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Use of transesophageal contrast echocardiography for excluding left atrial appendage thrombi in patients with atrial fibrillation before cardioversion.
    von der Recke G; Schmidt H; Illien S; Lüderitz B; Omran H
    J Am Soc Echocardiogr; 2002 Oct; 15(10 Pt 2):1256-61. PubMed ID: 12411914
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Cardioversion related thromboembolism: value of transesophageal echocardiography to guide cardioversion in patients with atrial fibrillation.
    Seidl K; Senges J
    Card Electrophysiol Rev; 2003 Dec; 7(4):392-6. PubMed ID: 15071262
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Role of transesophageal echocardiography among patients with atrial fibrillation undergoing electrophysiology testing.
    Priester R; Bunting T; Usher B; Chiaramida S; Taylor MH; Gregg D; Sturdivant JL; Leman RB; Wharton JM; Gold MR
    Am J Cardiol; 2009 Nov; 104(9):1256-8. PubMed ID: 19840572
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Usefulness of transesophageal echocardiography using a combined probe when converting atrial fibrillation to sinus rhythm.
    Scholten MF; Thornton AS; Jordaens LJ; Roelandt JR; Kerber RE; Kronzon I
    Am J Cardiol; 2004 Aug; 94(4):470-3. PubMed ID: 15325931
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Efficacy of transesophageal echocardiography-guided cardioversion of patients with atrial fibrillation at 6 months: a randomized controlled trial.
    Klein AL; Grimm RA; Jasper SE; Murray RD; Apperson-Hansen C; Lieber EA; Black IW; Davidoff R; Erbel R; Halperin JL; Orsinelli DA; Porter TR; Stoddard MF;
    Am Heart J; 2006 Feb; 151(2):380-9. PubMed ID: 16442904
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Usefulness of transoesophageal echocardiography before cardioversion in patients with atrial fibrillation and different anticoagulant regimens.
    Maltagliati A; Galli CA; Tamborini G; Calligaris A; Doria E; Salehi R; Pepi M
    Heart; 2006 Jul; 92(7):933-8. PubMed ID: 16284221
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Transesophageal echocardiography before and during direct current cardioversion of atrial fibrillation: evidence for "atrial stunning" as a mechanism of thromboembolic complications.
    Fatkin D; Kuchar DL; Thorburn CW; Feneley MP
    J Am Coll Cardiol; 1994 Feb; 23(2):307-16. PubMed ID: 8294679
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Prevention of embolic events after cardioversion of atrial fibrillation. Current and evolving strategies.
    Kinch JW; Davidoff R
    Arch Intern Med; 1995 Jul; 155(13):1353-60. PubMed ID: 7794083
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Cost-effectiveness of transesophageal echocardiographic-guided cardioversion: a decision analytic model for patients admitted to the hospital with atrial fibrillation.
    Seto TB; Taira DA; Tsevat J; Manning WJ
    J Am Coll Cardiol; 1997 Jan; 29(1):122-30. PubMed ID: 8996304
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Comparing TEE- vs Non-TEE-guided cardioversion of atrial fibrillation: The ENSURE-AF trial.
    Kozieł M; Merino JL; De Caterina R; Huber K; Jin J; Melino M; Goette A; Lip GYH;
    Eur J Clin Invest; 2020 May; 50(5):e13221. PubMed ID: 32150758
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Low-molecular-weight heparin in transesophageal echocardiography-guided cardioversion of atrial fibrillation.
    Wodlinger AM; Pieper JA
    Pharmacotherapy; 2003 Jan; 23(1):57-63. PubMed ID: 12523460
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Simultaneous transesophageal cardioversion and echocardiography: feasibility and safety.
    Mischke K; Schimpf T; Winograd R; Knackstedt C; Zarse M; Plisiene J; Hanrath P; Kelm M; Schauerte P
    Heart Rhythm; 2007 Mar; 4(3):304-7. PubMed ID: 17341393
    [TBL] [Abstract][Full Text] [Related]  

  • 39. The safety of low-molecular weight heparins for the prevention of thromboembolic events after cardioversion of atrial fibrillation.
    Yigit Z; Küçükoglu MS; Okçün B; Sansoy V; Güzelsoy D
    Jpn Heart J; 2003 May; 44(3):369-77. PubMed ID: 12825804
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Prevalence of atrial thrombi in patients with atrial fibrillation/flutter and subtherapeutic anticoagulation prior to cardioversion.
    Corrado G; Beretta S; Sormani L; Tadeo G; Foglia-Manzillo G; Tagliagambe LM; Santarone M
    Eur J Echocardiogr; 2004 Aug; 5(4):257-61. PubMed ID: 15219540
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 27.